TP53 and breast carcinoma: Here, we found that TP53-aberrant metastatic breast cancers had significantly higher TMB than TP53 wild-type metastatic breast cancers (median: 5.00 muts/Mb vs 1.44 muts/Mb; P = 0.004) (Figure 1D).